| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Settlement of fractional shares paid in cash | 0 | - |
| Net cash provided by (used in) financing activities | 69,352 | 68,027 |
| Net increase (decrease) in cash and cash equivalents | 71,170 | 83,900 |
| Cash and cash equivalents at beginning of period | 22,244 | - |
| Cash and cash equivalents at end of period | 93,414 | - |
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)